Ferroptosis is a form of cell death driven by iron and the uncontrolled breakdown of fats in cell membranes. First named in 2012, it is distinct from other well-known types of cell death like apoptosis (the orderly “self-destruct” process cells use during normal development). Ferroptosis has become one of the most actively studied topics in biomedical research because of its deep connections to cancer, neurodegenerative diseases, and organ damage.
How Ferroptosis Works
Every cell contains iron, which it needs for dozens of essential functions. But iron is also chemically reactive. When too much “free” iron accumulates inside a cell, it drives a chain reaction called lipid peroxidation: oxygen reacts with the polyunsaturated fatty acids (PUFAs) woven into the cell’s membranes, damaging them the way rust eats through metal. If this damage spirals out of control, the membrane breaks apart and the cell dies. That, in essence, is ferroptosis.
The process hinges on a specific vulnerability. PUFAs contain chemical structures that are especially prone to oxidation. An enzyme called ACSL4 helps incorporate these fatty acids into cell membranes in the first place, so cells with high ACSL4 activity tend to have more oxidation-prone membranes and are more susceptible to ferroptosis. Monounsaturated fatty acids, by contrast, lack that vulnerable structure and actually resist the chain reaction.
The Cell’s Built-In Defense System
Cells don’t normally die from lipid peroxidation because they run a continuous repair system. The centerpiece is an enzyme called GPX4. Think of GPX4 as a cleanup crew: it converts dangerous lipid peroxides into harmless alcohols before they can trigger a chain reaction. To do its job, GPX4 needs a supply of glutathione, a small molecule the cell builds from amino acids.
Getting those raw materials depends on a transporter in the cell membrane known as system xc-. This transporter pulls in cystine from outside the cell, and cystine is the key ingredient for making glutathione. Block the transporter and glutathione levels drop. Without glutathione, GPX4 can’t neutralize lipid peroxides. The peroxides accumulate, membranes rupture, and the cell undergoes ferroptosis. This is exactly how early experimental compounds were found to trigger the process, which led researchers to identify and name ferroptosis in 2012.
More recently, scientists have identified backup defense routes. One involves a protein called FSP1, which works alongside a molecule called CoQ10 to trap membrane-damaging radicals independently of GPX4. Cholesterol metabolism feeds into this pathway: when certain steps in cholesterol production are disrupted, CoQ10 and another lipid called squalene can accumulate, making cells more resistant to ferroptosis.
What Ferroptosis Looks Like Under a Microscope
Ferroptosis has a visual signature that sets it apart from other forms of cell death. Cells undergoing apoptosis show condensed, fragmented DNA. Cells dying from necrosis swell and burst. In ferroptosis, the most striking change happens to the mitochondria, the cell’s energy-producing compartments. They shrink noticeably, their internal folds (called cristae) flatten or disappear, and their outer membranes become unusually dense. The cell’s nucleus, by contrast, stays relatively normal. Researchers confirm ferroptosis in tissue samples by measuring chemical byproducts of lipid peroxidation, particularly malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), along with elevated levels of free iron and reactive oxygen species.
The Role of Iron
Iron inside a cell exists in different forms. Some is safely locked away in a storage protein called ferritin. Some is actively being used by enzymes. And some sits in what researchers call the “labile iron pool,” a small reserve of loosely bound iron that is chemically reactive and available for immediate use. It is this labile pool that fuels ferroptosis. When the pool grows too large, free iron catalyzes the formation of aggressive oxygen radicals through a well-known chemical process called the Fenton reaction.
The cell tightly regulates how much iron enters, how much gets stored, and how much gets exported. A receptor called transferrin receptor 1 (TfR1) brings iron into the cell. When iron levels are low, the cell can even break down its own ferritin stores to liberate more, a recycling process guided by a protein called NCOA4. Any shift that tips the balance toward excess free iron, whether from genetic variation, inflammation, or disease, raises the risk of ferroptosis. In experimental models, silencing the gene for TfR1 effectively prevents ferroptosis by cutting off the iron supply.
Ferroptosis and Cancer
Cancer cells often have altered iron metabolism and unusually high levels of reactive oxygen species, which makes them potentially vulnerable to ferroptosis. This has sparked intense interest in using ferroptosis as a weapon against tumors.
One promising angle involves the immune system. CD8+ T cells, the immune cells that hunt and kill cancer cells, release a signaling molecule called interferon gamma. Researchers have found that interferon gamma increases ACSL4 levels in tumor cells, loading their membranes with oxidation-prone fatty acids. At the same time, it weakens the cell’s ferroptosis defenses by reducing system xc- activity. The combination, especially when arachidonic acid (a common PUFA) is abundant in the tumor environment, can push cancer cells into ferroptosis. This means the immune system may already use ferroptosis as part of its natural anti-tumor response.
Experimental studies have shown that combining drugs that induce ferroptosis with immunotherapies, including both checkpoint inhibitors and CAR T-cell therapy, produces stronger anti-tumor effects than either approach alone. The ferroptosis inducers kill tumor cells directly while also making the dead cells more “visible” to the immune system, amplifying the immune attack. Clinical trials are still needed to confirm these effects in patients, but preclinical results have been encouraging, particularly in solid tumors that are traditionally difficult to treat with immunotherapy alone.
Ferroptosis in Brain Diseases
The brain is especially susceptible to ferroptosis for several reasons. It consumes a large share of the body’s oxygen, its cell membranes are rich in PUFAs, and certain brain regions accumulate iron progressively with age. These features create near-ideal conditions for runaway lipid peroxidation.
In Alzheimer’s disease, elevated iron has been found in the same brain regions where toxic protein plaques accumulate. In Parkinson’s disease, the substantia nigra, the region whose deterioration causes the characteristic tremor and movement problems, is known to have particularly high iron content. Researchers have observed that the molecular hallmarks of ferroptosis, including glutathione depletion, mitochondrial damage, and progressive oxidation, overlap substantially with the cellular changes seen in both diseases. This has led to growing interest in whether blocking ferroptosis could slow neurodegeneration, though this work is still in early stages.
How Researchers Block Ferroptosis
The most effective way to stop ferroptosis in experimental settings is to use compounds called radical-trapping antioxidants. These molecules insert themselves into cell membranes and intercept the chain reaction of lipid peroxidation before it spreads. Ferrostatin-1, one of the first such compounds identified, remains the standard reference tool in ferroptosis research. A related compound, Liproxstatin-1, works through the same general mechanism.
These inhibitors are primarily research tools rather than approved medicines, but they have been valuable for proving ferroptosis is involved in a given disease model. If blocking ferroptosis with one of these compounds protects cells or tissues from damage, it provides strong evidence that ferroptosis was driving the injury. Scientists are also exploring whether naturally occurring lipid-soluble antioxidants like vitamin E, which traps radicals in membranes by a similar mechanism, could offer some degree of protection in clinical settings.
Why Ferroptosis Matters Beyond the Lab
Ferroptosis sits at the intersection of iron metabolism, fat chemistry, and oxidative stress, three processes that go wrong in a wide range of human diseases. Beyond cancer and neurodegeneration, ferroptosis has been implicated in kidney injury, liver damage, heart disease following a heart attack, and stroke. In each case, the pattern is similar: overwhelmed antioxidant defenses, excess free iron, and membranes rich in vulnerable fatty acids.
Understanding ferroptosis gives researchers a new lens for diseases that were previously explained only in terms of apoptosis or inflammation. It also opens a two-sided therapeutic strategy: inducing ferroptosis in cells you want to eliminate (like cancer cells) and blocking it in cells you want to protect (like neurons or heart muscle after a blood supply is restored). That dual potential is a large part of why the field has grown so rapidly since the term was first coined just over a decade ago.